Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27, H1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015

Audit Opinion:

Unmodified conclusion issued by statutory auditors Deloitte Haskins & Sells for both standalone and consolidated financial results.

Key Financial Highlights [All amounts in ₹ million]:

Standalone Results:

Quarter ended September 30, 2026:

  • Revenue from Operations: ₹31,773.3 (Q2 FY26: ₹27,299.3, up 16.4% YoY)
  • Total Income: ₹32,801.3 (Q2 FY26: ₹28,894.5, up 13.5% YoY)
  • Net Profit: ₹7,235.8 (Q2 FY26: ₹5,813.7, up 24.5% YoY)
  • EPS: ₹12.58 basic and diluted (Q2 FY26: ₹10.01)

Half year ended September 30, 2026:

  • Revenue from Operations: ₹59,768.4 (H1 FY26: ₹55,267.6, up 8.1% YoY)
  • Total Income: ₹63,215.3 (H1 FY26: ₹57,700.5, up 9.6% YoY)
  • Net Profit: ₹14,608.0 (H1 FY26: ₹11,405.0, up 28.1% YoY)
  • EPS: ₹25.33 basic and diluted (H1 FY26: ₹19.64)

Balance Sheet (Standalone) as of September 30, 2026:

  • Cash and Cash Equivalents: ₹973.9 (March 31, 2026: ₹1,604.3)
  • Other Equity: ₹2,33,167.3 (March 31, 2026: ₹2,26,596.1)
  • Debt (Borrowings): ₹38,893.9 (March 31, 2026: ₹41,824.7)
  • Total Assets: ₹298,192.2 (March 31, 2026: ₹292,793.8)

Consolidated Results:

Quarter ended September 30, 2026:

  • Revenue from Operations: ₹1,02,632.9 (Q2 FY26: ₹82,857.0, up 23.9% YoY)
  • Total Income: ₹1,04,315.1 (Q2 FY26: ₹84,062.9, up 24.1% YoY)
  • Net Profit attributable to Owners: ₹11,260.8 (Q2 FY26: ₹8,484.5, up 32.7% YoY)
  • EPS: ₹19.57 basic and diluted (Q2 FY26: ₹14.61)

Half year ended September 30, 2026:

  • Revenue from Operations: ₹1,94,136.4 (H1 FY26: ₹1,61,538.4, up 20.2% YoY)
  • Total Income: ₹1,98,460.9 (H1 FY26: ₹1,63,793.4, up 21.2% YoY)
  • Net Profit attributable to Owners: ₹21,586.5 (H1 FY26: ₹16,732.0, up 29.0% YoY)
  • EPS: ₹37.52 basic and diluted (H1 FY26: ₹28.81)

Balance Sheet (Consolidated) as of September 30, 2026:

  • Cash and Cash Equivalents: ₹62,315.1 (March 31, 2026: ₹71,914.0)
  • Other Equity: ₹3,93,423.6 (March 31, 2026: ₹3,78,328.9)
  • Debt (Borrowings): ₹82,337.5 (March 31, 2026: ₹76,762.0)
  • Total Assets: ₹617,542.9 (March 31, 2026: ₹585,021.5)

Segment-wise Performance:

The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108.

Corporate Actions:

  • Dividend: Declared interim dividend of 700% i.e. ₹7.00 per equity share of ₹1/- each
  • Record Date: November 11, 2026 for payment of interim dividend
  • Payment Date: On or before November 20, 2026
  • Buyback: Completed buyback of 5,423,728 equity shares (0.93% of total) for aggregate ₹8,058 million including expenses

Other Significant Information:

  • Acquisitions: Completed acquisition of 100% membership interest in Lannett Company LLC and its subsidiaries for ₹23,218.3 million (USD 245.7 million) on June 29, 2026
  • Exceptional Items: H1 FY27 includes acquisition costs of ₹401.8 million related to Lannett acquisition
  • New Subsidiaries: Incorporated multiple new subsidiaries including Arrow Pharma Production SAS (France), PT Auro Pharm Indonesia, Auropharm Overseas Limited, Ai Biochem USA INC, Avogent Lifesciences Private Limited
  • Associate Investments: Acquired 26% stake in Swarnaakshu Solar Power Private Limited (₹5.2 million) and invested in Garuda Renewables Private Limited (₹165.0 million)
  • Scheme Filings: Submitted schemes of amalgamation for various subsidiary mergers with NCLT
  • Labor Code Impact: Recognized incremental cost of ₹173.8 million in FY26 due to New Labour Codes implementation